{"protocolSection": {"identificationModule": {"nctId": "NCT03019887", "orgStudyIdInfo": {"id": "673"}, "organization": {"fullName": "Juntendo University", "class": "OTHER"}, "briefTitle": "Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction", "officialTitle": "Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction in Patients Undergoing High-dose Antipsychotic Therapy"}, "statusModule": {"statusVerifiedDate": "2021-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-04"}, "primaryCompletionDateStruct": {"date": "2017-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-01-11", "studyFirstSubmitQcDate": "2017-01-12", "studyFirstPostDateStruct": {"date": "2017-01-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-01-19", "resultsFirstSubmitQcDate": "2021-08-11", "resultsFirstPostDateStruct": {"date": "2021-09-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-08-11", "lastUpdatePostDateStruct": {"date": "2021-09-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Ryota Ataniya", "investigatorTitle": "Clinician, graduate student", "investigatorAffiliation": "Juntendo University"}, "leadSponsor": {"name": "Juntendo University", "class": "OTHER"}}, "descriptionModule": {"briefSummary": "To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.", "detailedDescription": "We attempted to reduce the dose of antipsychotics to \u22641000-mg chlorpromazine eq./day. The dose was gradually reduced at a rate of \u226450-mg chlorpromazine eq./week, and the reduction was discontinued if the subjects relapsed. The differences in baseline cognitive function were analyzed between the patients with no relapse and relapse groups."}, "conditionsModule": {"conditions": ["Schizophrenia Relapse"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 139, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "reduction group", "type": "EXPERIMENTAL", "description": "dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week", "interventionNames": ["Drug: reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine"]}], "interventions": [{"type": "DRUG", "name": "reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine", "armGroupLabels": ["reduction group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Relapse", "description": "The definition of relapse is as follows 1.50% or greater increase in total DIEPSS score, 2. an increase in the total PANSS score of 25% or more from baseline, 3. deliberate self-injury, 4. emergence of clinically significant suicidal ideation, 5. violent behavior resulting in clinically significant injury to another person or property damage.", "timeFrame": "One year after the baseline cognitive function test or three months after the end of dose reduction, whichever came first."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* inpatients with a diagnosis of schizophrenia, and\n* those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg chlorpromazine eq./day.\n\nExclusion Criteria:\n\n* mental retardation,\n* substance abuse or dependence,\n* a history of major head trauma,\n* serious medical or neurological disorders, or\n* depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Takahashi Tadashi", "affiliation": "Okada hospital", "role": "STUDY_CHAIR"}, {"name": "Mikiro Saito", "affiliation": "Okada hospital", "role": "STUDY_CHAIR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Dose Reduction", "description": "patients who reduced dose of antipsychotics"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "139"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "130"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Reduction Group", "description": "Group of patients with schizophrenia undergoing high-dose therapy (\\>1000-mg chlorpromazine eq./day) We attempted to reduce the dose of antipsychotics to \u22641000-mg chlorpromazine eq./day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "130"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.5", "spread": "11.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "50"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "80"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "130"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Relapse", "description": "The definition of relapse is as follows 1.50% or greater increase in total DIEPSS score, 2. an increase in the total PANSS score of 25% or more from baseline, 3. deliberate self-injury, 4. emergence of clinically significant suicidal ideation, 5. violent behavior resulting in clinically significant injury to another person or property damage.", "populationDescription": "patients with schizophrenia taking more than 1000 mg / day of antipsychotics, reduce their dose to less than 1000 mg", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "One year after the baseline cognitive function test or three months after the end of dose reduction, whichever came first.", "groups": [{"id": "OG000", "title": "Dose Reduction", "description": "patients who reduced dose of antipsychotics"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "130"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Dose Reduction", "description": "patients who reduced dose of antipsychotics", "seriousNumAffected": 0, "seriousNumAtRisk": 130, "otherNumAffected": 51, "otherNumAtRisk": 130}], "otherEvents": [{"term": "increase in the total PANSS score from baseline", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numAffected": 51, "numAtRisk": 130}]}, {"term": "increase in total DIEPSS score", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}]}, {"term": "violent behavior", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 130}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Ryota Ataniya", "organization": "Okada hospital", "email": "ryotaataniya@pbt.nir.jp", "phone": "+81-4-7124-6151"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012008", "term": "Recurrence"}, {"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M14850", "name": "Recurrence", "asFound": "Relapse", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008728", "term": "Methotrimeprazine"}, {"id": "D000006220", "term": "Haloperidol"}, {"id": "D000077152", "term": "Olanzapine"}, {"id": "D000018967", "term": "Risperidone"}, {"id": "D000068180", "term": "Aripiprazole"}, {"id": "D000069348", "term": "Quetiapine Fumarate"}, {"id": "D000068882", "term": "Paliperidone Palmitate"}, {"id": "C000033563", "term": "Haloperidol decanoate"}, {"id": "D000010546", "term": "Perphenazine"}], "ancestors": [{"id": "D000012702", "term": "Serotonin Antagonists"}, {"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000018492", "term": "Dopamine Antagonists"}, {"id": "D000015259", "term": "Dopamine Agents"}, {"id": "D000000932", "term": "Antiemetics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000005765", "term": "Gastrointestinal Agents"}, {"id": "D000017367", "term": "Selective Serotonin Reuptake Inhibitors"}, {"id": "D000014179", "term": "Neurotransmitter Uptake Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000018491", "term": "Dopamine Agonists"}, {"id": "D000058825", "term": "Serotonin 5-HT1 Receptor Agonists"}, {"id": "D000017366", "term": "Serotonin Receptor Agonists"}, {"id": "D000058830", "term": "Serotonin 5-HT2 Receptor Antagonists"}, {"id": "D000065127", "term": "Dopamine D2 Receptor Antagonists"}, {"id": "D000018726", "term": "Anti-Dyskinesia Agents"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}], "browseLeaves": [{"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M229", "name": "Aripiprazole", "asFound": "Association", "relevance": "HIGH"}, {"id": "M9312", "name": "Haloperidol", "asFound": "0.75", "relevance": "HIGH"}, {"id": "M215475", "name": "Haloperidol decanoate", "asFound": "0.75", "relevance": "HIGH"}, {"id": "M20999", "name": "Risperidone", "asFound": "Stable", "relevance": "HIGH"}, {"id": "M1675", "name": "Olanzapine", "asFound": "Cavity", "relevance": "HIGH"}, {"id": "M5987", "name": "Chlorpromazine", "relevance": "LOW"}, {"id": "M13454", "name": "Perphenazine", "asFound": "Omeprazole 20 mg", "relevance": "HIGH"}, {"id": "M11704", "name": "Methotrimeprazine", "asFound": "Recombinant Human Nerve Growth Factor", "relevance": "HIGH"}, {"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M329", "name": "Paliperidone Palmitate", "asFound": "Operating", "relevance": "HIGH"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20596", "name": "Dopamine Antagonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}, {"id": "M4251", "name": "Antiemetics", "relevance": "LOW"}, {"id": "M8881", "name": "Gastrointestinal Agents", "relevance": "LOW"}, {"id": "M19649", "name": "Selective Serotonin Reuptake Inhibitors", "relevance": "LOW"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M20595", "name": "Dopamine Agonists", "relevance": "LOW"}, {"id": "M29240", "name": "Serotonin 5-HT1 Receptor Agonists", "relevance": "LOW"}, {"id": "M19648", "name": "Serotonin Receptor Agonists", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnDyAg", "name": "Anti-Dyskinesia Agents"}, {"abbrev": "AnEm", "name": "Antiemetics"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}